The estimated Net Worth of David L. Lucchino is at least $11.6 Million dollars as of 18 August 2023. Mr. Lucchino owns over 5,922 units of Frequency Therapeutics Inc stock worth over $190,123 and over the last 5 years he sold FREQ stock worth over $4,033,045. In addition, he makes $7,364,600 as President, Chief Executive Officer, Co-Founder, and Director at Frequency Therapeutics Inc.
Sign up
Mr. Lucchino FREQ stock SEC Form 4 insiders trading
David has made over 52 trades of the Frequency Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,922 units of FREQ stock worth $3,257 on 18 August 2023.
The largest trade he's ever made was exercising 113,690 units of Frequency Therapeutics Inc stock on 21 June 2021 worth over $69,351. On average, David trades about 11,415 units every 22 days since 2019. As of 18 August 2023 he still owns at least 633,744 units of Frequency Therapeutics Inc stock.
You can see the complete history of Mr. Lucchino stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Lucchino biography
David L. Lucchino serves as President, Chief Executive Officer, Co-Founder, Director of the Company. From December 2014 until June 2016, Mr. Lucchino served as the President and Chief Executive Officer of Entrega Bio, a PureTech Health-founded biotechnology company focused on oral drug delivery technology. Prior to that, Mr. Lucchino co-founded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr. Lucchino oversaw the development of the company’s lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr. Lucchino worked at the investment firm Polaris Partners. Mr. Lucchino is the chairman of the board of directors of MassBio, a non-profit organization that represents and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Governor Charlie Baker as a member of the Commonwealth’s Economic Planning Council. Mr. Lucchino also serves as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of Advisors of Life Science Cares. Mr. Lucchino holds an MBA from the Massachusetts Institute of Technology’s, or MIT’s, Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University.
What is the salary of David Lucchino?
As the President, Chief Executive Officer, Co-Founder, and Director of Frequency Therapeutics Inc, the total compensation of David Lucchino at Frequency Therapeutics Inc is $7,364,600. There are no executives at Frequency Therapeutics Inc getting paid more.
How old is David Lucchino?
David Lucchino is 51, he's been the President, Chief Executive Officer, Co-Founder, and Director of Frequency Therapeutics Inc since 2014. There are 10 older and 6 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
What's David Lucchino's mailing address?
David's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC., 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Insiders trading at Frequency Therapeutics Inc
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer, and Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
What does Frequency Therapeutics Inc do?
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
What does Frequency Therapeutics Inc's logo look like?
Complete history of Mr. Lucchino stock trades at Frequency Therapeutics Inc
Frequency Therapeutics Inc executives and stock owners
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Lucchino,
President, Chief Executive Officer, Co-Founder, Director -
Christopher Loose,
Co-Founder, Chief Scientific Officer -
Carl LeBel,
Chief Development Officer -
David L. Lucchino,
Co-Founder, Pres, CEO & Director -
Wendy S. Arnold,
Chief People Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Robert Langer,
Independent Director -
Marc Cohen,
Lead Independent Chairman of the Board Director -
Joel Marcus,
Independent Director -
Michael Huang,
Independent Director -
Timothy Barberich,
Independent Director -
Carlo Tanzi,
IR Contact Officer -
Cynthia Feldmann,
Independent Director -
Dana Hilt,
Chief Medical Officer -
Ajay Rai,
Vice President - Business Development -
Richard Mitrano,
Vice President of Finance and Operations -
Wendy Arnold,
Chief People Officer -
William Mclean,
Co-Founder, Vice President - Biology and Regenerative Medicine -
Dr. Carl P. LeBel,
Chief Devel. Officer -
Dr. Christopher R. Loose,
CoÂ-Founder & Chief Scientific Officer -
Dr. William W. Chin M.D.,
Sr. VP of Translational Medicine -
Dr. Dana C. Hilt,
Chief Medical Officer -
Dr. Jeff Hrkach,
Sr. VP of Technology Devel. -
Richard J. Mitrano,
VP of Fin. & Operations -
William J. McLean Ph.D.,
Co-founder & Sr. VP of Hearing Biology and Translational Research -
Quentin Mc Cubbin,
Chief Manufacturing Officer -
James E Deerfield Mgmt L.P....,
-
Peter P. Pfreundschuh,
Chief Financial Officer -
Michael Bookman,
General Counsel and Secretary